The company announced on Wednesday that it had signed a non-exclusive deal with Merck, allowing the latter to use Shasun's proprietary cross-coupling copper technology to manufacture and commercialise bulk drugs. |
Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
The company announced on Wednesday that it had signed a non-exclusive deal with Merck, allowing the latter to use Shasun's proprietary cross-coupling copper technology to manufacture and commercialise bulk drugs. |
First Published: Feb 28 2008 | 12:00 AM IST